Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363650 | 1.00 | EPHX2 (0.56) | EPHX2HRH3LIPEEPHX1PANK3 | |
| SCHEMBL12225516 | 0.86 | EPHX2 (0.54) | EPHX2HRH3LIPEEPHX1PANK3 | |
| SCHEMBL25225367 | 0.83 | ALDH1A1 (0.57) | EPHX2KCNH2ALDH1A1 | |
| SCHEMBL2539421 | 0.81 | HRH3 (0.56) | EPHX2HRH3LIPEPANK3KCNH2 | |
| SCHEMBL2539413 | 0.81 | HRH3 (0.56) | EPHX2HRH3LIPEPANK3KCNH2 | |
| SCHEMBL19506327 | 0.80 | HRH3 (0.58) | EPHX2HRH3LIPEPANK3KCNH2 | |
| SCHEMBL19506243 | 0.80 | HRH3 (0.57) | EPHX2HRH3LIPEPANK3KCNH2 | |
| SCHEMBL4368982 | 0.80 | HRH3 (0.49) | EPHX2HRH3LIPEPANK3KCNH2 | |
| SCHEMBL4368988 | 0.80 | HRH3 (0.49) | EPHX2HRH3LIPEPANK3KCNH2 | |
| SCHEMBL16828777 | 0.79 | HRH3 (0.62) | EPHX2HRH3LIPEPANK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-2003131-A1 | AMINOPYRROLIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | MC4R, MC5R, MC2R | EPHX2 4720/4885HRH3 323/4885LIPE 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.